Peptides: BPC-157, TB-500 and What the Rules Actually Are

Peptides have become the most confusing topic in regenerative medicine. Patients hear one thing from a clinic, something else from a compounding pharmacy, and something else again from a podcast. The claims are made with enormous confidence in every direction, which is usually the tell that nobody is reading the primary sources.

This page collects what Don Buford, MD has written about peptides for orthopedic problems: what the substances are, what the regulations say, and what has and has not been demonstrated in humans.

Where the regulatory line actually falls

Compounding pharmacies operate under section 503A of the Federal Food, Drug, and Cosmetic Act, and they may only work from certain bulk drug substances. In practice a substance generally has to have an official USP or National Formulary monograph, already be part of an FDA approved drug product, or appear on the FDA's 503A Bulks List.

BPC-157, TB-500 and injectable GHK-Cu are not FDA approved drugs, and they are not on the formal 503A Bulks List. That is where the entire controversy starts, and it is why the same peptide can be described as legal by one seller and prohibited by another. The honest answer is that the landscape has been shifting since 2023 and moved considerably through 2025 and 2026. Anyone speaking about it with total certainty is overselling their position.

What the human evidence shows, and does not

The gap between how peptides are marketed and what has been tested in people is very wide. For orthopedic use in particular there is little registered human safety or placebo controlled work to point at. That is not the same as saying these substances do nothing. It means the studies that would tell us have largely not been done, and a patient being offered one is being offered something closer to a hypothesis than a treatment.

Compare that with platelet rich plasma, where more than thirty level 1 randomized trials exist for knee arthritis alone, and where the dose itself has been measured and correlated with outcome. When a patient asks whether to try a peptide or high dose PRP for an orthopedic problem, the evidence base is not a close call.

What this practice does

Texas Orthobiologics does not sell peptides. The orthobiologic procedures offered here use platelet rich plasma and bone marrow concentrate taken from your own body, measured in the office so the dose is known, and placed under ultrasound guidance. If you are considering a peptide, the questions worth asking are the same ones that apply to every orthobiologic: what exactly is in it, what pathway does it fall under, and what human data exists for the problem you actually have.